BR112022012164A2 - Composto de ácido hialurônico e pelo menos um heterociclo derivado de purina e/ou pirimidina, composto para uso, estrutura de suporte implantável e formulação farmacêutica - Google Patents

Composto de ácido hialurônico e pelo menos um heterociclo derivado de purina e/ou pirimidina, composto para uso, estrutura de suporte implantável e formulação farmacêutica

Info

Publication number
BR112022012164A2
BR112022012164A2 BR112022012164A BR112022012164A BR112022012164A2 BR 112022012164 A2 BR112022012164 A2 BR 112022012164A2 BR 112022012164 A BR112022012164 A BR 112022012164A BR 112022012164 A BR112022012164 A BR 112022012164A BR 112022012164 A2 BR112022012164 A2 BR 112022012164A2
Authority
BR
Brazil
Prior art keywords
compound
hyaluronic acid
purine
pyrimidine
support structure
Prior art date
Application number
BR112022012164A
Other languages
English (en)
Inventor
Manenti Demetrio
Abbiati Giuliana
Original Assignee
Trb Chemedica Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70295628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112022012164(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trb Chemedica Int Sa filed Critical Trb Chemedica Int Sa
Publication of BR112022012164A2 publication Critical patent/BR112022012164A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A61L2300/214—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSTO DE ÁCIDO HIALURÔNICO E PELO MENOS UM HETEROCICLO DERIVADO DE PURINA E/OU PIRIMIDINA, COMPOSTO PARA USO, ESTRUTURA DE SUPORTE IMPLANTÁVEL E FORMULAÇÃO FARMACÊUTICA. A presente invenção refere-se à utilização de derivados entre ácido hialurônico, compostos heterocíclicos e aminoácidos de ocorrência natural em forma simples, oligomérica ou polimérica para o tratamento de doenças esqueléticas, em particular na regeneração de tecidos ósseos e cartilaginosos.
BR112022012164A 2019-12-20 2020-12-18 Composto de ácido hialurônico e pelo menos um heterociclo derivado de purina e/ou pirimidina, composto para uso, estrutura de suporte implantável e formulação farmacêutica BR112022012164A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102019000025126A IT201900025126A1 (it) 2019-12-20 2019-12-20 Uso di derivati dell’acido ialuronico nella rigenerazione dei tessuti ossei e cartilaginei
PCT/IB2020/062186 WO2021124249A1 (en) 2019-12-20 2020-12-18 Use of hyaluronic acid derivatives in the regeneration of bone and cartilage tissues

Publications (1)

Publication Number Publication Date
BR112022012164A2 true BR112022012164A2 (pt) 2022-09-13

Family

ID=70295628

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012164A BR112022012164A2 (pt) 2019-12-20 2020-12-18 Composto de ácido hialurônico e pelo menos um heterociclo derivado de purina e/ou pirimidina, composto para uso, estrutura de suporte implantável e formulação farmacêutica

Country Status (14)

Country Link
US (1) US20230018851A1 (pt)
EP (1) EP4076428A1 (pt)
JP (1) JP7719992B2 (pt)
KR (1) KR20220140712A (pt)
CN (1) CN115135318B (pt)
BR (1) BR112022012164A2 (pt)
CA (1) CA3162397A1 (pt)
CO (1) CO2022010207A2 (pt)
IL (1) IL294054B1 (pt)
IT (1) IT201900025126A1 (pt)
MX (1) MX2022007614A (pt)
UA (1) UA129389C2 (pt)
WO (1) WO2021124249A1 (pt)
ZA (1) ZA202207058B (pt)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041523A1 (en) * 1995-06-12 1996-12-27 Yeda Research And Development Co., Ltd. Fgf9 as a specific ligand for fgfr3
US6761887B1 (en) * 1998-11-16 2004-07-13 Osiris Therapeutics, Inc. Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells
WO2000029552A1 (en) * 1998-11-16 2000-05-25 Osiris Therapeutics, Inc. Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells
KR20030070150A (ko) * 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Ｐｄｅ4 이소자임 억제제로서 유용한 에테르 유도체
US6710096B2 (en) 2002-07-22 2004-03-23 Basf Corporation Polyether polyol for foam applications
ITMI20021666A1 (it) 2002-07-26 2004-01-26 Jasper Ltd Liability Co Derivati dell'acido ialuronico
TW200633733A (en) * 2004-12-07 2006-10-01 Gelwell Biotech Corp Biomaterials for guided tissue regeneration and drug delivery
CN101622348A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
KR101706642B1 (ko) * 2015-02-04 2017-02-17 주식회사 엑소스템텍 연골세포로 분화되고 있는 줄기세포로부터 추출된 엑소좀을 포함하는 연골세포 분화 유도 또는 연골조직 재생용 조성물
US12029765B2 (en) * 2017-06-13 2024-07-09 Houn Simon Hsia Compositions and methods for treating cancer
TW202000899A (zh) * 2018-03-06 2020-01-01 美商艾沛邦股份有限公司 可注射之即用軟骨、肌腱及韌帶修復組合物及使用方法
CN112969706A (zh) * 2018-09-20 2021-06-15 卡尔蒂拉戈有限责任公司 刺激细胞外基质合成的葡糖胺的氨基酸衍生物和包含其的药物组合物

Also Published As

Publication number Publication date
IL294054A (en) 2022-08-01
US20230018851A1 (en) 2023-01-19
IT201900025126A1 (it) 2021-06-20
MX2022007614A (es) 2022-10-20
EP4076428A1 (en) 2022-10-26
CA3162397A1 (en) 2021-06-24
WO2021124249A1 (en) 2021-06-24
AU2020410540A1 (en) 2022-07-21
CO2022010207A2 (es) 2022-10-21
CN115135318A (zh) 2022-09-30
KR20220140712A (ko) 2022-10-18
UA129389C2 (uk) 2025-04-09
CN115135318B (zh) 2025-06-24
IL294054B1 (en) 2026-08-01
JP7719992B2 (ja) 2025-08-07
JP2023506953A (ja) 2023-02-20
ZA202207058B (en) 2023-05-31

Similar Documents

Publication Publication Date Title
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
BR112018004175A2 (pt) novo composto pirazolo[3,4-d]pirimidina ou sal deste
PH12020551205A1 (en) Fap inhibitors
MX381913B (es) Composiciones y metodos para el tratamiento de la mielofibrosis.
BRPI0517426A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente
ECSP088217A (es) Formas de cristal delta y épsilon de mesilato de imatinib
BR112015020235A2 (pt) fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit
BR112017016487A2 (pt) 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
BRPI0409198A (pt) derivados quinolin-2-ona para o tratamento de doenças de vias aéreas
BRPI0613570A8 (pt) composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto.
BR112015022469A2 (pt) peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu
MX338088B (es) Imidazoquinolinas y derivados de pirimidina como moduladores potentes de los procesos angiogenicos impulsados por el factor de crecimiento endotelial vascular (vegf).
CL2019003324A1 (es) Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745)
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BR112019011462A2 (pt) peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.
CL2008003545A1 (es) Compuestos derivados del acido [(imidazol-1-il)-1-hidroxi-1-fosfono-etil]-fosfonico; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de una resorcion osea excesiva o inapropiada o de una enfermedad causada por una prenilacion excesiva de proteinas objetivo.
BR112015019412A2 (pt) inibidores de bace1
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
BR112018012183A2 (pt) composição cosmética e seu uso, formulação cosmética
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25G Requested change of headquarter approved

Owner name: TRB CHEMEDICA INTERNATIONAL SA (CH)